These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

673 related articles for article (PubMed ID: 28865552)

  • 21. Supplementation with a recombinant human chorionic gonadotropin microdose leads to similar outcomes in ovarian stimulation with recombinant follicle-stimulating hormone using either a gonadotropin-releasing hormone agonist or antagonist for pituitary suppression.
    Cavagna M; Maldonado LG; de Souza Bonetti TC; de Almeida Ferreira Braga DP; Iaconelli A; Borges E
    Fertil Steril; 2010 Jun; 94(1):167-72. PubMed ID: 19342035
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fertility outcomes in women after controlled ovarian stimulation with gonadotropin releasing hormone agonist long protocol: fresh versus frozen embryo transfer.
    Ding X; Yang J; Li L; Yang N; Lan L; Huang G; Ye H
    BMC Pregnancy Childbirth; 2021 Mar; 21(1):207. PubMed ID: 33711956
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients.
    Turan V; Bedoschi G; Moy F; Oktay K
    Fertil Steril; 2013 Dec; 100(6):1681-5.e1. PubMed ID: 24055050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?
    Lalami I; Labrosse J; Cedrin-Durnerin I; Comtet M; Vinolas C; Krief F; Sifer C; Peigne M; Grynberg M
    Reprod Biol Endocrinol; 2022 Jun; 20(1):87. PubMed ID: 35690817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does prolonged pituitary down-regulation with gonadotropin-releasing hormone agonist improve the live-birth rate in in vitro fertilization treatment?
    Ren J; Sha A; Han D; Li P; Geng J; Ma C
    Fertil Steril; 2014 Jul; 102(1):75-81. PubMed ID: 24746740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual trigger with gonadotropin-releasing hormone agonist and recombinant human chorionic gonadotropin improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles.
    Seval MM; Özmen B; Atabekoğlu C; Şükür YE; Şimşir C; Kan Ö; Sönmezer M
    J Obstet Gynaecol Res; 2016 Sep; 42(9):1146-51. PubMed ID: 27199084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duphaston and human menopausal gonadotropin protocol in normally ovulatory women undergoing controlled ovarian hyperstimulation during in vitro fertilization/intracytoplasmic sperm injection treatments in combination with embryo cryopreservation.
    Zhu X; Ye H; Fu Y
    Fertil Steril; 2017 Sep; 108(3):505-512.e2. PubMed ID: 28697910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of dual trigger with combination GnRH agonist and hCG versus hCG alone trigger of oocyte maturation for normal ovarian responders.
    Zhou X; Guo P; Chen X; Ye D; Liu Y; Chen S
    Int J Gynaecol Obstet; 2018 Jun; 141(3):327-331. PubMed ID: 29388691
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation.
    Eldar-Geva T; Zylber-Haran E; Babayof R; Halevy-Shalem T; Ben-Chetrit A; Tsafrir A; Varshaver I; Brooks B; Margalioth EJ
    Reprod Biomed Online; 2007 Feb; 14(2):148-54. PubMed ID: 17298715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual trigger using recombinant HCG and gonadotropin-releasing hormone agonist improve oocyte maturity and embryo grading for normal responders in GnRH antagonist cycles: Randomized controlled trial.
    Ali SS; Elsenosy E; Sayed GH; Farghaly TA; Youssef AA; Badran E; Abbas AM; Abdelaleem AA
    J Gynecol Obstet Hum Reprod; 2020 May; 49(5):101728. PubMed ID: 32173633
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response.
    Volodarsky-Perel A; Cohen Y; Arab S; Son WY; Suarthana E; Dahan MH; Tulandi T; Buckett W
    Hum Reprod; 2019 Mar; 34(3):530-538. PubMed ID: 30689898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone.
    O'Neill KE; Senapati S; Maina I; Gracia C; Dokras A
    J Assist Reprod Genet; 2016 Sep; 33(9):1175-84. PubMed ID: 27349252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GnRH agonist trigger and a freeze-all strategy to prevent ovarian hyperstimulation syndrome: a retrospective study of OHSS risk and pregnancy rates.
    Atkinson P; Koch J; Ledger WL
    Aust N Z J Obstet Gynaecol; 2014 Dec; 54(6):581-5. PubMed ID: 25476811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.
    Reddy J; Turan V; Bedoschi G; Moy F; Oktay K
    J Assist Reprod Genet; 2014 Jul; 31(7):927-32. PubMed ID: 24854484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
    Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
    Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes.
    Martínez F; Clua E; Devesa M; Rodríguez I; Arroyo G; González C; Solé M; Tur R; Coroleu B; Barri PN
    Fertil Steril; 2014 Nov; 102(5):1307-11. PubMed ID: 25154677
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Euploidy rates between cycles triggered with gonadotropin-releasing hormone agonist and human chorionic gonadotropin.
    Thorne J; Loza A; Kaye L; Nulsen J; Benadiva C; Grow D; Engmann L
    Fertil Steril; 2019 Aug; 112(2):258-265. PubMed ID: 31103285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.